Database : MEDLINE
Search on : diabetic and neuropathies [Words]
References found : 14284 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1429 go to page                         

  1 / 14284 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29309710
[Au] Autor:Zhu GC; Tsai KL; Chen YW; Hung CH
[Ad] Address:Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
[Ti] Title:Neural Mobilization Attenuates Mechanical Allodynia and Decreases Proinflammatory Cytokine Concentrations in Rats With Painful Diabetic Neuropathy.
[So] Source:Phys Ther;, 2017 Dec 22.
[Is] ISSN:1538-6724
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Background: Painful diabetic neuropathy (PDN) is a common complication in patients with diabetes. It is related to ischemic nerve damage and the increase in the levels of proinflammatory mediators, such as tumor necrosis factor α (TNF-α) and interleukin 1ß (IL-1ß). Neural mobilization may have the potential to alleviate PDN, but it has not yet been tested. Also, the physiological mechanism of neural mobilization is unclear. Objective: The objective of this study was to investigate treatment effect and physiological mechanism of neural mobilization. Design: This was an experimental study using rats with streptozocin (or streptozotocin)-induced type 1 diabetes. Methods: Three groups were used in the study, the control group (vehicle), the diabetes group (PDN group), and the neural mobilization treatment group (PDN-NM group) (n = 6). Rats in the vehicle group were healthy rats. Rats in the PDN and PDN-NM groups were rats with diabetes. Rats in the PDN-NM group received treatment in the right sciatic nerve, whereas rats in the PDN group did not. Mechanical pain sensitivity and the levels of IL-1ß and TNF-α in the sciatic nerve branches and trunk, the L4 to L6 dorsal horn ganglion, and the spinal cord dorsal horn were measured. Results: Mechanical allodynia was alleviated after treatment, but the effect was limited to the treatment side. The concentrations of proinflammatory cytokines were decreased in the nerves that received treatment compared with those on the other side, indicating that neural mobilization may reduce mechanical sensitivity by decreasing the concentrations of local sensitizing agents. Limitations: A limitation of this study was that no direct measurement of nerve blood flow was done. Conclusions: The results of this study showed that neural mobilization effectively alleviated mechanical allodynia in rats with PDN. The side that received treatment had lower concentrations of TNF-α and IL-1ß in the sciatic nerve branches and sciatic nerve trunk; this result may have been related to the alleviation of mechanical allodynia.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/ptj/pzx124

  2 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29511897
[Au] Autor:Gonzalez-Duarte A
[Ad] Address:Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México. gonzalezduarte@aol.com.
[Ti] Title:Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
[So] Source:Clin Auton Res;, 2018 Mar 06.
[Is] ISSN:1619-1560
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:PURPOSE: Hereditary transthyretin amyloidosis (hATTR amyloidosis) is a progressive disease primarily characterized by adult-onset sensory, motor, and autonomic neuropathy. In this article, we discuss the pathophysiology and principal findings of autonomic neuropathy in hATTR amyloidosis, the most common methods of assessment and progression, and its relation as a predictive risk factor or a measure of progression in the natural history of the disease. METHODS: A literature search was performed using the terms "autonomic neuropathy," "dysautonomia," and "autonomic symptoms" in patients with hereditary transthyretin amyloidosis and familial amyloid polyneuropathy. RESULTS: Various scales to measure autonomic function have been employed, particularly within the major clinical trials, to assess novel therapies for the disease. Most of the evaluations were taken from diabetic clinical trials. Questionnaires include the COMPASS-31 and Norfolk QOL autonomic nerve function domain, whereas clinical evaluations comprise HRDB and the orthostatic tolerance test. Several treatment options are being employed although only diflunisal and tafamidis have reported improvement in the autonomic abnormalities. CONCLUSIONS: Autonomic nerves are often affected before motor nerve impairment, and dysautonomia may support the diagnosis of hATTR amyloidosis when differentiating from other adult-onset progressive neuropathies and from other types of amyloidosis. Most of the progression of autonomic dysfunction is seen in early stages of the disease, commonly before motor impairment or affection of the overall quality of life. Unfortunately, there is no current single standardized approach to evaluate dysautonomia in hATTR amyloidosis.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.1007/s10286-018-0514-2

  3 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29458425
[Au] Autor:Yell PC; Burns DK; Dittmar EG; White CL; Cai C
[Ad] Address:Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, 75390, USA.
[Ti] Title:Diffuse microvascular C5b-9 deposition is a common feature in muscle and nerve biopsies from diabetic patients.
[So] Source:Acta Neuropathol Commun;6(1):11, 2018 02 20.
[Is] ISSN:2051-5960
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Terminal complement complex deposition in endomysial capillaries detected by a C5b-9 immunostain is considered a diagnostic feature for dermatomyositis. However, we found widespread microvascular C5b-9 reactivity in a substantial subset of muscle biopsies with denervation changes, and in nerve biopsies of peripheral neuropathies, particularly in patients with diabetes. It is unclear whether the presence of C5b-9 deposition signifies active immune-mediated vascular injury that requires immune suppression therapy. We retrospectively identified 63 nerve biopsies in patients with a documented history of diabetes, 26 of which had concomitant muscle biopsies, as well as 54 control nerve biopsies in patients without a documented diabetes history, 18 of which had concomitant muscle biopsies. C5b-9 immunostain was performed on all cases. 87% of the nerve biopsies and 92% of the muscle biopsies from diabetic patients showed microvascular C5b-9 reactivity, compared to 34% and 50% in non-diabetic patients. The differences were statistically significant (p < 0.0001 for nerve and p = 0.002 for muscle). The C5b-9 reactivity was generally proportional to the extent of microvascular sclerosis in diabetic patients, but unrelated to inflammation or vasculitis. C5b-9 deposition in micro-vasculature in both muscle and nerve is therefore a common feature in patients with diabetic neuropathies and may have diagnostic utility. Precaution needs to be taken before using muscle capillary C5b-9 reactivity as evidence of myositis.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.1186/s40478-018-0512-6

  4 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29460914
[Au] Autor:Chukanova EI; Chukanova AS
[Ad] Address:Pirogov Russian National Research Medical University, Moscow, Russia.
[Ti] Title:Al'fa-lipoevaia kislota v lechenii diabeticheskoi polineiropatii. [Alpha-lipoic acid in the treatment of diabetic polyneuropathy].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;118(1):103-109, 2018.
[Is] ISSN:1997-7298
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:The issues of classification, pathogenesis, pathomorphology and treatment of diabetic polyneuropathy (DPN) are addressed. Pathogenetic mechanisms of the action of alpha-lipoic acid in treatment of DPN are justified. The authors present the results of randomized placebo-controlled trials of alpha-lipoic acid that revealed the high clinical efficacy and absence of side-effects even during the long-term treatment.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:In-Data-Review
[do] DOI:10.17116/jnevro201811811103-109

  5 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29330601
[Au] Autor:Kalkan M; Bayram A; Gökay F; Cura HS; Mutlu C
[Ad] Address:Department of ENT, Kayseri Training and Research Hospital, Sanayi Mah. Atatürk Bulvari Hastane Cad. No:78, 38010, Kayseri, Turkey.
[Ti] Title:Assessment of vestibular-evoked myogenic potentials and video head impulse test in type 2 diabetes mellitus patients with or without polyneuropathy.
[So] Source:Eur Arch Otorhinolaryngol;275(3):719-724, 2018 Mar.
[Is] ISSN:1434-4726
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:This study aimed to compare cervical vestibular-evoked myogenic potentials (cVEMP), ocular vestibular-evoked myogenic potentials (oVEMP) and video head impulse test (vHIT) results between patients with type 2 diabetes mellitus (DM) or diabetic polyneuropathy (DPN) and healthy controls to determine vestibular end-organ pathologies. The participants in the present study consisted of three groups: the type 2 DM group (n = 33 patients), the DPN group (n = 33 patients), and the age- and sex-matched control group (n = 35). Cervical VEMP, oVEMP and vHIT were performed for each participant in the study and test results were compared between the groups. Peak-to-peak amplitudes of cVEMP (p13-n21) and oVEMP (n10-p15) were significantly lower in the DM and DPN groups than the control group. The values of vHIT were not statistically different between the groups. To our knowledge, the present study is the first report investigating oVEMP and cVEMP responses combined with vHIT findings in patients with DM and DPN. Vestibular end-organ pathologies can be determined via clinical vestibular diagnostic tools in spite of prominent vestibular symptoms in patients with type 2 DM as well as patients with DPN.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[St] Status:In-Process
[do] DOI:10.1007/s00405-018-4873-z

  6 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29453140
[Au] Autor:Chung JO; Park SY; Han JH; Cho DH; Chung DJ; Chung MY
[Ad] Address:Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Medical School, 8 Hak-Dong, Dong-Gu, Gwangju 501-757, Republic of Korea.
[Ti] Title:Serum apolipoprotein A-1 concentrations and the prevalence of cardiovascular autonomic neuropathy in individuals with type 2 diabetes.
[So] Source:J Diabetes Complications;, 2018 Jan 31.
[Is] ISSN:1873-460X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To evaluate the relationship between levels of serum apolipoproteins and the prevalence of cardiovascular autonomic neuropathy (CAN) in type 2 diabetes. METHODS: In total, 3199 individuals with type 2 diabetes were investigated in a cross-sectional study. The diagnosis of CAN was made based on the results of a cardiovascular reflex test. Serum apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) levels were measured. RESULTS: Serum apoA-1 levels were significantly low in individuals with CAN, but there was no significant association between serum apoB levels and CAN. According to the degree of cardiovascular autonomic dysfunction, the average apoA-I levels were significantly different after adjusting for other covariates (normal, 1.32 g/l, 95% confidence interval [CI] 1.30-1.35; early, 1.29 g/l, 95% CI 1.27-1.31; definite, 1.27 g/l, 95% CI 1.25-1.30; P for trend = 0.010). In the multivariable analysis, the statistically significant association between apoA-I and CAN remained after adjusting for the risk factors (odds ratio per standard deviation increase in the log-transformed value, 0.65; 95% CI, 0.43-0.97, P = 0.036). Additional adjustments for serum high-sensitivity C-reactive protein (or fibrinogen) concentrations eliminated this relationship. CONCLUSIONS: Serum apoA-I levels are inversely associated with the prevalence of CAN in individuals with type 2 diabetes. Our data also suggest that a putatively increased risk of CAN associated with decreased apoA-I levels might be mediated by correlated increases in the levels of inflammatory markers.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180217
[Lr] Last revision date:180217
[St] Status:Publisher

  7 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29378101
[Au] Autor:Serhiyenko VA
[Ti] Title:[Effects of omega-3 polyunsaturated fatty acids on the state of insulin resistance, the content of some pro- and antiinflammatory factors in patients with type 2 diabetes mellitus and cardiovascular autonomic neuropathy].
[So] Source:Vopr Pitan;84(6):76-82, 2015.
[Is] ISSN:0042-8833
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:We have investigated the influence of the long-chain ω-3 polyunsaturated fatty acids (ω-3 PUFA) administration on the insulin resistance parameters, levels of high sensitivity C-reactive protein (hsCRP), some pro- and anti-inflammatory cytokines in patients with type 2 diabetes mellitus (T2 DM) and cardiovascular autonomic neuropathy (CAN). The study involved 12 patients with T2 DM without verified cardiovascular diseases (CVD), 36 patients with T2 DM and functional stage of CAN, of median age 50­59 years, disease duration 1­6 years and HbA1c levels ­ 7.1±0.6%. 15 healthy subjects were control group. Screening for CAN, that included five standard cardiovascular tests, was performed. The levels of blood glucose, HbA1c, immunoreactive insulin (IRI), hsCRP, tumor necrosis factor α (TNFα), interleukin (IL)-6, IL-8 and IL-10 were measured. The index of insulin resistance (HOMA-IR) and TNFα/IL-10 ratio were calculated. Patients with T2 DM and CAN were divided into 2 groups: patients of the 1st group (group of comparison, n=15) received standard glucose-lowering therapy; patients of the 2nd group (n=21) received one capsule/day of the ω-3 PUFA (∼90% ethyl ester of PUFA (1000 mg), in particular eicosapentaenoic ­ 460 mg, docosahexaenoic acid ­ 380 mg and 4 mg α-tocopherol acetate) in addition to the standard therapy. The duration of the study was 3 months. Obtained results showed, that development of CAN in patients with T2 DM is accompanied by increase of the IRI (26.6±1.73 mcIU/ml, p<0.001 ­ compared to the control; p1<0.001 ­ compared to T2 DM patients without CVD); hsCRP (2.77±0.24 mg/l, p<0.001, p1<0,001); TNFα (5.75±0.24 pg/ml, p<0.001, p1<0.001); IL-6 (5.88±0.38 pg/ml, p<0.001, p1<0.001); IL-8 (6.65±0.3 pg/ml, p<0.001, p1>0.05); IL-10 (15.86±1.4 pg/ml, p<0.05, p1>0.05) levels; TNFα/IL-10 (44.2±3.57%, p<0.01, p1<0.05) and HOMA-IR. After 3 months of treatment no statistically significant changes (p>0.05) of investigated parameters, in particular levels of IRI (-6.8±2.0%); hsCRP (-7.2±1.63%); TNFα (-6.1±1.0%); IL-6 (-5.8±1.77%); IL-8 (-3.9±1.57%); IL-10 (-3.7±2.34%); TNFα/IL-10 (-0.5±2.3%) in patients from the group of comparison were found. The administration of ω-3 PUFA to patients with T2 DM and CAN promoted to the statistically significant decrease in hsCRP (-14.8±2.91%, p<0.05), TNFα (-14.1±2.15%, p<0.01), IL-6 (-13.5±2.7%, p<0.05), IL-8 (-9.8±2.13%, p<0.05), TNFα/IL-10 ratio (-34.6±1.93%, p<0.05); a slighty decrease in the content of the IRI (-10.3±1.1%, p>0.05), IL-10 (+7.9 ±6.42%, p>0.05), HOMA-IR was observed. Obtained results could witness, that prescription of ω-3 PUFA leads to decrease of the proinflammatory immune response activity and allows to consider ω-3 PUFA as a promising medicine in treatment and/or prevention of CAN in patients with DM 2.
[Mh] MeSH terms primary: Cardiovascular Diseases
Diabetes Mellitus, Type 2
Diabetic Neuropathies
Fatty Acids, Omega-3/administration & dosage
Insulin Resistance
[Mh] MeSH terms secundary: Cardiovascular Diseases/blood
Cardiovascular Diseases/drug therapy
Cytokines/blood
Diabetes Mellitus, Type 2/blood
Diabetes Mellitus, Type 2/drug therapy
Diabetic Neuropathies/blood
Diabetic Neuropathies/drug therapy
Female
Humans
Inflammation/blood
Inflammation/drug therapy
Inflammation Mediators/blood
Male
Middle Aged
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Cytokines); 0 (Fatty Acids, Omega-3); 0 (Inflammation Mediators)
[Em] Entry month:1802
[Cu] Class update date: 180216
[Lr] Last revision date:180216
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  8 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29419686
[Au] Autor:Wang X; Lin H; Xu S; Jin Y; Zhang R
[Ad] Address:Shenzhen Bao'an Traditional Chinese Medicine Hospital Group, Guangzhou University of Chinese Medicine, Shenzhen.
[Ti] Title:The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
[So] Source:Medicine (Baltimore);97(6):e9828, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Diabetic peripheral neuropathy (DPN) is a common long-term complication of diabetes mellitus, affecting patients in the world. Epalrestat combined with α-lipoic acid (ALA) is the most frequent combine therapy used in the DPN researches. We aim to assess the effectiveness and safety of epalrestat combined with ALA in patients with DPN, compare with epalrestat alone. METHODS: We will search Cochrane Library, PubMed, Wanfang Data, China National Knowledge Infrastructure, VIP Chinese Science and Technology Journals Database, and Chinese Biomedical Database from inception until October 31th, 2017. Inclusion the randomized controlled trials and clinical control trials of combine therapy which evaluate clinical efficacy and side effect in people with DPN. Data extraction and risk of bias assessments will be independently conducted by 2 reviewers. The primary outcome measures will be total effective rate, motor nerve conduction velocity (MNCV), sensory nerve conduction velocity (SNCV), Toronto clinical scoring system (TCSS), and total symptom score (TSS). All statistical analyses will be performed using RevMan V.5.3 software. RESULTS: This review will evaluate the total effective rate, nerve conduction velocity, TCSS, TSS, and safety of ALA combined with epalrestat for patients with DPN, compare with epalrestat alone. CONCLUSION: Our study will provide evidence to assess whether epalrestat combined with ALA is an optional treatment for patients with DPN.
[Mh] MeSH terms primary: Diabetic Neuropathies/drug therapy
Meta-Analysis as Topic
Rhodanine/analogs & derivatives
Thiazolidines
Thioctic Acid
[Mh] MeSH terms secundary: Antioxidants/administration & dosage
Antioxidants/adverse effects
Drug Therapy, Combination
Enzyme Inhibitors/administration & dosage
Enzyme Inhibitors/adverse effects
Humans
Randomized Controlled Trials as Topic
Research Design
Rhodanine/administration & dosage
Rhodanine/adverse effects
Thiazolidines/administration & dosage
Thiazolidines/adverse effects
Thioctic Acid/administration & dosage
Thioctic Acid/adverse effects
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antioxidants); 0 (Enzyme Inhibitors); 0 (Thiazolidines); 424DV0807X (epalrestat); 73Y7P0K73Y (Thioctic Acid); 7O50LKL2G8 (Rhodanine)
[Em] Entry month:1802
[Cu] Class update date: 180214
[Lr] Last revision date:180214
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009828

  9 / 14284 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29341577
[Au] Autor:Biocanin V; Milic M; Vucetic M; Vasovic M; Zivadinovic D; Zivadinovic M; Cetkovic D; Calasan D; Brkovic B
[Ti] Title:Apical root-end filling with tricalcium silicate-based cement in a patient with diabetes mellitus: A case report.
[So] Source:Vojnosanit Pregl;73(12):1173-7, 2016 Dec.
[Is] ISSN:0042-8450
[Cp] Country of publication:Serbia
[La] Language:eng
[Ab] Abstract:Introduction: The material used for root-end filling has to be biocompatible with adjacent periapical tissue and to stimulate its regenerative processes. Tricalcium silicate cement (TSC), as a new dental material, shows good sealing properties with dentin, high compression strengths and better marginal adaptation than commonly used root-end filling materials. Although optimal postoperative healing of periapical tissues is mainly influenced by characteristics of end-root material used, it could sometimes be affected by the influence of systemic diseases, such as diabetes mellitus (DM). Case report: We presented apical healing of the upper central incisor, retrofilled with TSC, in a diabetic patient (type 2 DM) with peripheral neuropathy. Standard root-end resection of upper central incisor was accompanied by retropreparation using ultrasonic retrotips to the depth of 3 mm and retrofilling with TSC. Post-operatively, the surgical wound healed uneventfully. However, the patient reported undefined dull pain in the operated area that could possibly be attributed to undiagnosed intraoral diabetic peripheral neuropathy, what was evaluated clinically. Conclusion: Although TSC presents a suitable material for apical root-end filling in the treatment of chronic periradicular lesions a possible presence of systemic diseases, like type 2 DM, has to be considered in the treatment outcome estimation.
[Mh] MeSH terms primary: Calcium Compounds/therapeutic use
Diabetes Mellitus, Type 2/complications
Diabetic Neuropathies/etiology
Periapical Diseases/surgery
Root Canal Filling Materials/therapeutic use
Root Canal Obturation
Silicates/therapeutic use
[Mh] MeSH terms secundary: Diabetes Mellitus, Type 2/diagnosis
Diabetes Mellitus, Type 2/physiopathology
Diabetic Neuropathies/diagnosis
Diabetic Neuropathies/physiopathology
Humans
Male
Middle Aged
Pain Perception
Pain Threshold
Pain, Postoperative/complications
Pain, Postoperative/physiopathology
Periapical Diseases/complications
Periapical Diseases/diagnostic imaging
Radiography, Dental
Root Canal Obturation/adverse effects
Treatment Outcome
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Calcium Compounds); 0 (Root Canal Filling Materials); 0 (Silicates); 404G39282C (tricalcium silicate)
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[Js] Journal subset:IM
[Da] Date of entry for processing:180118
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150606137B

  10 / 14284 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29317209
[Au] Autor:Gong Y; Zhu Y; Zhu B; Si X; Heng D; Tang Y; Sun X; Lin L
[Ad] Address:Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
[Ti] Title:LncRNA MALAT1 is up-regulated in diabetic gastroparesis and involved in high-glucose-induced cellular processes in human gastric smooth muscle cells.
[So] Source:Biochem Biophys Res Commun;496(2):401-406, 2018 02 05.
[Is] ISSN:1090-2104
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Recent years, widespread long non-coding RNAs (lncRNAs) were identified and known as regulator of gene expression. Diabetic gastroparesis (DGP) is one of the most common chronic complications of diabetes mellitus. There was no research reported the role of lncRNAs in DGP. In this study, we firstly established a rat model of DGP by STZ injection. Then, we detected the expression of MALAT1 and found that expression of MALAT1 was up-regulated in rat model of DGP, comparing to the control group (P < .01). Furthermore, we revealed that MALAT1 expression was increased in the samples from diabetic patients with DGP symptoms, in comparison with the control. In addition, we demonstrated that the inhibition of MALAT1 increased the expression of α-SMA and SM myosin heavy chains, reduced the cell viability, inhibited the potential of cell migration and induced cell apoptosis in human gastric smooth muscle cells (SMCs). Ultimately, we found that the regulation of MALAT1 expression modulated the function of high-glucose stimulation in human gastric SMCs. Therefore, our study firstly indicated that MALAT1 was up-regulated in DGP and played an important role in the pathogenesis of DGP.
[Mh] MeSH terms primary: Diabetes Mellitus, Experimental/genetics
Diabetic Neuropathies/genetics
Gastroparesis/genetics
Myocytes, Smooth Muscle/metabolism
RNA, Long Noncoding/genetics
Stomach/metabolism
[Mh] MeSH terms secundary: Actins/genetics
Actins/metabolism
Animals
Apoptosis/drug effects
Apoptosis/genetics
Cell Movement/drug effects
Cell Proliferation/drug effects
Diabetes Mellitus, Experimental/chemically induced
Diabetes Mellitus, Experimental/complications
Diabetes Mellitus, Experimental/metabolism
Diabetic Neuropathies/chemically induced
Diabetic Neuropathies/complications
Diabetic Neuropathies/metabolism
Gastric Emptying
Gastroparesis/chemically induced
Gastroparesis/complications
Gastroparesis/metabolism
Gene Expression Regulation
Glucose/pharmacology
Humans
Male
Myocytes, Smooth Muscle/drug effects
Myocytes, Smooth Muscle/pathology
Myosin Heavy Chains/genetics
Myosin Heavy Chains/metabolism
Primary Cell Culture
RNA, Long Noncoding/metabolism
Rats
Rats, Sprague-Dawley
Signal Transduction
Stomach/drug effects
Stomach/pathology
Streptozocin
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (ACTA2 protein, human); 0 (Actins); 0 (MALAT1 long non-coding RNA, human); 0 (RNA, Long Noncoding); 5W494URQ81 (Streptozocin); EC 3.6.4.1 (Myosin Heavy Chains); IY9XDZ35W2 (Glucose)
[Em] Entry month:1802
[Cu] Class update date: 180213
[Lr] Last revision date:180213
[Js] Journal subset:IM
[Da] Date of entry for processing:180111
[St] Status:MEDLINE


page 1 of 1429 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information